Products - Psoriasis | Topic | NICE

Showing 32 products

Date | Title

Status: PublishedRemove ‘Status: Published’ filter

Bimekizumab for treating active psoriatic arthritis (TA916)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 October 2023
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2023
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 August 2022
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 July 2022
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 October 2021
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 September 2021
Risankizumab for treating moderate to severe plaque psoriasis (TA596)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 August 2019
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 April 2019
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 April 2019
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2019
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 October 2018
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2018
Guselkumab for treating moderate to severe plaque psoriasis (TA521)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 March 2018
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 September 2017
Psoriasis: assessment and management (CG153)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
1 September 2017
Published:
24 October 2012
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 July 2017
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 May 2017
Ixekizumab for treating moderate to severe plaque psoriasis (TA442)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 April 2017
Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
3 March 2017
Published:
23 September 2009
Ustekinumab for treating active psoriatic arthritis (TA340)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
3 March 2017
Published:
4 June 2015
Apremilast for treating active psoriatic arthritis (TA433)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2017
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 November 2016
Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Golimumab for the treatment of psoriatic arthritis (TA220)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2011
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 August 2010
Adalimumab for the treatment of adults with psoriasis (TA146)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2008
Infliximab for the treatment of adults with psoriasis (TA134)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2008
Grenz rays therapy for inflammatory skin conditions (IPG236)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 November 2007
Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 July 2006
Psoriasis (QS40)
Product type:
Quality standard
Published:
6 August 2013